Evidence-informed frameworks for cost-effective cancer care and prevention in low, middle, and high-income countries

The Lancet Oncology

Volumn 15, Issue 3, 2014, Pages

  Chalkidou, Kalipso ^a   Marquez, Patricio ^b   Dhillon, Preet K ^c   Teerawattananon, Yot ^d   Anothaisintawee, Thunyarat ^e   Gadelha, Carlos Augusto Grabois ^f   Sullivan, Richard ^g  

^a NATIONAL INSTITUTE FOR HEALTH AND CARE EXCELLENCE   (United Kingdom)

^b WORLD BANK   (United States)

^c PUBLIC HEALTH FOUNDATION OF INDIA   (India)

^d MINISTRY OF PUBLIC HEALTH   (Thailand)

^e MAHIDOL UNIVERSITY   (Thailand)

^f INSTITUTO OSWALDO CRUZ   (Brazil)

^g KING'S COLLEGE LONDON   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

AFGHANISTAN; AFRICA SOUTH OF THE SAHARA; BRAZIL; CANCER MORTALITY; CANCER PALLIATIVE THERAPY; CANCER PREVENTION; CANCER STAGING; CANCER SURVIVAL; CANCER THERAPY; COST CONTROL; COST EFFECTIVENESS ANALYSIS; ECONOMIC DEVELOPMENT; EMPIRICAL RESEARCH; EVIDENCE BASED MEDICINE; GOVERNMENT; HEALTH CARE ACCESS; HEALTH CARE COST; HEALTH CARE DELIVERY; HEALTH CARE DISPARITY; HEALTH CARE POLICY; HEALTH CARE QUALITY; HEALTH CARE SYSTEM; HIGH INCOME COUNTRY; HUMAN; INDIA; LOW INCOME COUNTRY; MALIGNANT NEOPLASTIC DISEASE; MIDDLE INCOME COUNTRY; NATIONAL HEALTH SERVICE; PATIENT CARE; PRACTICE GUIDELINE; PRIORITY JOURNAL; PUBLIC HEALTH; QUALITY OF LIFE; REVIEW; RISK REDUCTION; SOCIAL STATUS; SOCIOECONOMICS; THAILAND; UNITED KINGDOM; UNITED STATES;

COST OF ILLNESS; COST-BENEFIT ANALYSIS; DEVELOPED COUNTRIES; DEVELOPING COUNTRIES; HEALTH CARE COSTS; HUMANS; NEOPLASMS; WORLD HEALTH ORGANIZATION;

EID: 84896716017     PISSN: 14702045     EISSN: 14745488     Source Type: Journal    
DOI: 10.1016/S1470-2045(13)70547-3     Document Type: Review

References (86)

1. Albreht T, McKee M, Alexe DM, Coleman MP, Martin-Moreno JM Making progress against cancer in Europe in 2008. Eur J Cancer 2008, 44:1451-1456.
2. Meropol NJ, Schulman KA Cost of cancer care: issues and implications. J Clin Oncol 2007, 25:180-186.
3. Begley S Is high spending on cancer care 'worth it'? (accessed Nov 19, 2013). http://www.reuters.com/article/2012/04/09/us-cancercare-idUSBRE8380SA20120409.
4. Sullivan R, Peppercorn J, Sikora K, et al. Delivering affordable cancer care in high-income countries. Lancet Oncol 2011, 12:933-980.
5. Mathers CD, Loncar D Projections of global mortality and burden of disease from 2002 to 2030. PLoS Med 2006, 3:e442.
6. Smith TJ, Hillner BE Ensuring quality cancer care by the use of clinical practice guidelines and critical pathways. J Clin Oncol 2001, 19:2886-2897.
7. Experts in chronic myeloid leukemia. The price of drugs for chronic myeloid leukemia (CML) is a reflection of the unsustainable prices of cancer drugs: from the perspective of a large group of CML experts. Blood 2013, 121:4439-4442.
8. Ades F, Senterre C, de Azambuja E, et al. Discrepancies in cancer incidence and mortality and its relationship to health expenditure in the 27 European Union member states. Ann Oncol 2013, 24:2897-2902.
9. Luengo-Fernandez R, Leal J, Gray A, Sullivan R Economic burden of cancer across the European Union: a population-based cost analysis. Lancet Oncol 2013, 14:1165-1174.
10. Kantarjian HM, Fojo T, Mathisen M, Zwelling LA Cancer drugs in the United States: justum pretium-the just price. J Clin Oncol 2013, 31:3600-3604.
11. Banegas MP, Yabroff KR Out of pocket, out of sight? An unmeasured component of the burden of cancer. J Natl Cancer Inst 2013, 105:252-253.
12. Davidoff AJ, Erten M, Shaffer T, et al. Out-of-pocket health care expenditure burden for Medicare beneficiaries with cancer. Cancer 2013, 119:1257-1265.
13. Ubel PA, Abernethy AP, Zafar SY Full disclosure: out-of-pocket costs as side effects. N Engl J Med 2013, 369:1484-1486.
14. Chustecka Z $32 million: cost of overtreatment of prostate cancer (accessed Nov 19, 2013). http://www.medscape.com/viewarticle/779223.
15. Mariotto AB, Yabroff KR, Shao Y, Feuer EJ, Brown ML Projections of the cost of cancer care in the United States: 2010-2020. J Natl Cancer Inst 2011, 103:117-128.
16. Clinical practice guidelines we can trust Institute of Medicine, (accessed Nov 20, 2013). http://www.iom.edu/Reports/2011/Clinical-Practice-Guidelines-We-Can-Trust.aspx.
17. Engelberg J, Parsons CA, Tefft N First, do no harm: financial conflicts in medicine (accessed Nov 20, 2013). http://papers.ssrn.com/sol3/papers.cfm?abstract_id=2297094.
18. Nguyen T-A-H, Dechartres A, Belgherbi S, Ravaud P Public availability of results of trials assessing cancer drugs in the United States. J Clin Oncol 2013, 31:2998-3003.
19. Bach PB Limits on Medicare's ability to control rising spending on cancer drugs. N Engl J Med 2009, 360:626-633.
20. Stein R Review of prostate cancer drug Provenge renews medical cost-benefit debate (accessed Nov 20, 2013). http://www.washingtonpost.com/wp-dyn/content/article/2010/11/07/AR2010110705205.html.
21. Newcomer LN Changing physician incentives for cancer care to reward better patient outcomes instead of use of more costly drugs. Health Aff (Millwood) 2012, 31:780-785.
22. Neumann PJ, Weinstein MC Legislating against use of cost-effectiveness information. N Engl J Med 2010, 363:1495-1497.
23. Bennett WL, Odelola OA, Wilson LM, et al. Evaluation of guideline recommendations on oral medications for type 2 diabetes mellitus: a systematic review. Ann Intern Med 2012, 156:27-36.
24. Chalkidou K, Culyer A, Littlejohns P, Doyle N, Hoy A Imbalances in funding for clinical and public health research in the UK: can NICE research recommendations make a difference?. Evid Policy 2008, 4:355-369.
25. Skin cancer prevention: information, resources and environmental changes (PH32) National Institute for Health and Care Excellence, (accessed Nov 20, 2013). http://guidance.nice.org.uk/PH32.
26. Linley WG, Hughes DA Societal views on NICE, cancer drugs fund and value-based pricing criteria for prioritising medicines: a cross-sectional survey of 4118 adults in Great Britain. Health Econ 2013, 22:948-964.
27. Faden RR, Chalkidou K, Appleby J, Waters HR, Leider JP Expensive cancer drugs: a comparison between the United States and the United Kingdom. Milbank Q 2009, 87:789-819.
28. Claxton K, Martin S, Soares M, et al. Methods for the estimation of the NICE cost effectiveness threshold (accessed Nov 20, 2013). http://www.york.ac.uk/media/che/documents/papers/researchpapers/CHERP81_methods_estimation_NICE_costeffectiveness_threshold_(Nov2013).pdf.
29. Autier P, Boniol M, La Vecchia C, et al. Disparities in breast cancer mortality trends between 30 European countries: retrospective trend analysis of WHO mortality database. BMJ 2010, 341:c3620.
30. Jemal A, Bray F, Center MM, Ferlay J, Ward E, Forman D Global cancer statistics. CA Cancer J Clin 2011, 61:69-90.
31. Progress in implementing measles mortality reduction strategies: India, 2010-2011. MMWR Morb Mortal Wkly Rep; 60: 1315-19.
32. Consolidated report of population based cancer registries, 2001-2004 2006, NCRP, National Cancer Registry Program, Bangalore.
33. Rural health statistics in India, 2012 Statistics Division, Ministry of Health and Family WelfareMinistry of Health and Family Welfare, Government of IndiaGovernment of India, (accessed Nov 20, 2013). http://nrhm.gov.in/images/pdf/publication/RHS-2012.pdf.
34. Sankaranarayanan R, Black RJ, Swaminathan R, Parkin DM An overview of cancer survival in developing countries. IARC Sci Publ 1998, 145:135-173.
35. Reddy KS, Patel V, Jha P, Paul VK, Kumar AKS, Dandona L Towards achievement of universal health care in India by 2020: a call to action. Lancet 2011, 377:760-768. for The Lancet India Group for Universal Healthcare.
36. Balarajan Y, Selvaraj S, Subramanian SV Health care and equity in India. Lancet 2011, 377:505-515.
37. High level expert group report on universal health coverage for India 2011, HLEG, Planning Commission of India, New Delhi.
38. Dikshit R, Gupta PC, Ramasundarahettige C, et al. Cancer mortality in India: a nationally representative survey. Lancet 2012, 379:1807-1816. for the Million Death Study Collaborators.
39. Nair KS, Raj S, Tiwari VK, Piang LK Cost of treatment for cancer: experiences of patients in public hospitals in India. Asian Pac J Cancer Prev 2013, 14:5049-5054.
40. Mahal A, Karan A, Fan VY, Engelgau M The economic burden of cancers on Indian households. PLoS One 2013, 8:e71853.
41. Sengupta A, Joseph RK, Modi S, Syam N Economic constraints to access to essential medicines in India 2008, Centre for Technology and Development, Society for Economic and Social Studies, New Delhi.
42. Yamabhai I, Mohara A, Tantivess S, Chaisiri K, Teerawattananon Y Government use licenses in Thailand: an assessment of the health and economic impacts. Global Health 2011, 7:28.
43. Anothaisintawee T, Teerawattananon Y, Tanthai N Cost-utility of screening breast cancer with mammography once in a life time in Thai women 2013, Health Intervention and Technology Assessment Program, Bangkok.
44. Almeida Ribeiro A, Sampaio MC, Barradas R Condições de Saúde da população brasileira. Política e Sistemas de Saúde no Brasil 2012, 143-181. Fiocruz and Cebes, Rio de Janeiro. L. Giovanella, S. Escorel, L. de Vasconcelos Costa Lobato, J. de Carvalho Noronha, A.I. de Carvalho (Eds.).
45. Moreno-Serra R, Smith PC Does progress towards universal health coverage improve population health?. Lancet 2012, 380:917-923.
46. Gadelha CAG, Maldonado J, Vargas M, Barbosa PR, Costa LS A dinâmica do Sistema Produtivo da Saúde: inovação e complexo econÔmico-industrial 2012, Fiocruz, Rio de Janeiro.
47. WHO model lists of essential medicines WHO, (accessed Nov 26, 2013). http://www.who.int/medicines/publications/essentialmedicines/en/.
48. Priority-setting in health: building institutions for smarter public spending Center for Global Development, (accessed Jan 7, 2014). http://international.cgdev.org/sites/default/files/1426240_file_priority_setting_global_health_FINAL_0.pdf.
49. Essential medicines selection: trastuzumab (addition)-adults WHO, (accessed Nov 20, 2013). http://www.who.int/selection_medicines/committees/expert/19/applications/trastuzumab/en/.
50. Marquez P, Farrington JL The challenge of non-communicable diseases and road traffic injuries in sub-Saharan Africa: an overview 2013, World Bank, Washington DC.
51. Parkin DM, Sitas F, Chirenje M, Stein L, Abratt R, Wabinga H Part I: cancer in Indigenous Africans-burden, distribution, and trends. Lancet Oncol 2008, 9:683-692.
52. World development report 2012: gender equality and development 2011, World Bank, The World Bank, Washington DC.
53. Cervical cancer incidence and mortality worldwide in 2008: summary IARC, (accessed Nov 20, 2013). http://globocan.iarc.fr/factsheets/cancers/cervix.asp.
54. Tackling cervical cancer: improving access to cervical cancer services for women in southern Africa Southern Africa Litigation Centre, (accessed Nov 20, 2013). http://www.southernafricalitigationcentre.org/1/wp-content/uploads/2012/11/CERVICAL-CANCER-Report1.pdf.
55. Ramogola-Masire D, de Klerk R, Monare B, Ratshaa B, Ratshaa HM, Zetola NM Cervical cancer prevention in HIV-infected women using the "see and treat" approach in Botswana. J Acquir Immune Defic Syndr 2012, 59:308-313.
56. Human papillomavirus vaccine support GAVI Alliance, (accessed Nov 20, 2013). http://www.gavialliance.org/support/nvs/human-papillomavirus-vaccine-support.
57. Glassman A Separating the good from the bad on HPV (accessed Nov 20, 2013). http://international.cgdev.org/blog/separating-good-bad-hpv.
58. Strong L, Wali A, Sondorp E Health policy in Afghanistan: two years of rapid change-a review of the process from 2001 to 2003 (accessed Nov 20, 2013). http://crises.lshtm.ac.uk/files/2008/10/Health-Policy-in-Afghanistan-two-years-of-rapid-change.pdf.
59. Afghanistan reconstruction: despite some progress, deteriorating security and other obstacles continue to threaten achievment of US goals US Government Accountability Office, (accessed Nov 20, 2013). http://www.gao.gov/assets/250/247264.pdf.
60. A basic package of health services for Afghanistan, 2005/1384 Islamic Republic of Afghanistan, Ministry of Public HealthMinistry of Public Health, (accessed Nov 20, 2013). http://moph.gov.af/Content/Media/Documents/BPHS-2005-FINAL29122010162945969.pdf.
61. MoPH joins the family of NICE (National Institute for Health and Clinical Excellence), UK Ministry of Public Health, Islamic Republic of AfghanistanIslamic Republic of Afghanistan, (accessed Nov 20, 2013). http://moph.gov.af/en/news/20391.
62. Engelgau MM, El-Saharty S, Kudesia P, Rajan V, Rosenhouse S, Okamoto K Capitalizing on the demographic transition: tackling non communicable diseases in south Asia 2011, World Bank, Washington DC.
63. National health policy: towards a healthier Botswana Republic of Botswana, (accessed Nov 21, 2013). http://www.bistand.iogt.se/Global/NHP%20Nov%202011%20Parliament.pdf.
64. de Martel C, Ferlay J, Franceschi S, et al. Global burden of cancers attributable to infections in 2008: a review and synthetic analysis. Lancet Oncol 2012, 13:607-615.
65. Peto R, Darby S, Deo H, Silcocks P, Whitley E, Doll R Smoking, smoking cessation, and lung cancer in the UK since 1950: combination of national statistics with two case-control studies. BMJ 2000, 321:323-329.
66. Ahmad Kiadaliri A, Jarl J, Gavriilidis G, Gerdtham UG Alcohol drinking cessation and the risk of laryngeal and pharyngeal cancers: a systematic review and meta-analysis. PLoS One 2013, 8:e58158.
67. McTiernan A, Porter P, Potter JD Breast cancer prevention in countries with diverse resources. Cancer 2008, 113(suppl):2325-2330.
68. Mittra I, Mishra GA, Singh S, et al. A cluster randomized, controlled trial of breast and cervix cancer screening in Mumbai, India: methodology and interim results after three rounds of screening. Int J Cancer 2010, 126:976-984.
69. Sankaranarayanan R, Nene BM, Shastri SS, et al. HPV screening for cervical cancer in rural India. N Engl J Med 2009, 360:1385-1394.
70. Sankaranarayanan R, Ramadas K, Thomas G, et al. Effect of screening on oral cancer mortality in Kerala, India: a cluster-randomised controlled trial. Lancet 2005, 365:1927-1933. for the Trivandrum Oral Cancer Screening Study Group.
71. Santesso N, Schünemann H, Blumenthal P, et al. World Health Organization guidelines: use of cryotherapy for cervical intraepithelial neoplasia. Int J Gynaecol Obstet 2012, 118:97-102. for the World Health Organization Steering Committee, for the Recommendations on the Use of Cryotherapyfor the Recommendations on the Use of Cryotherapy, for Cervical Cancer Preventionfor Cervical Cancer Prevention.
72. André N, Banavali S, Snihur Y, Pasquier E Has the time come for metronomics in low-income and middle-income countries?. Lancet Oncol 2013, 14:e239-e248.
73. Putthasri W, Tangcharoensathien V, Mugem S, Jindawatana W Geographical distribution and utilization of mammography in Thailand 2004, vol 8:84-91. World Health Organization, Regional Office for South-East Asia, New Delhi, no 1. Regional Health Forum (Ed.).
74. Anothaisintawee T, Teerawattananon Y, Wiratkapun C, et al. Developing and validating breast cancer risk prediction model in Thai women 2013, Mahidol University, Bangkok.
75. Cancer facts and figures 2007 American Cancer Society, (accessed Nov 21, 2013). http://www.cancer.org/research/cancerfactsstatistics/cancerfactsfigures2007/index.
76. Bakitas M, Lyons KD, Hegel MT, et al. Effects of a palliative care intervention on clinical outcomes in patients with advanced cancer: the Project ENABLE II randomized controlled trial. JAMA 2009, 302:741-749.
77. Gorokhovich L, Chalkidou K, Shankar R Improving access to innovative medicines in emerging markets: evidence and diplomacy as alternatives to the unsustainable status quo. J Health Diplomacy 2013, published online Aug 20., (accessed Nov 21, 2013). http://www.ghd-net.org/abstracts/volume-1/8.
78. UK and India to work together on evidence-informed healthcare policy and practice UK Government, (accessed Jan 8, 2014). https://www.gov.uk/government/world-location-news/uk-and-india-to-work-together-on-evidence-informed-healthcare-policy-and-practice.
79. NICE signs memorandum of understanding with the China National Health Development Research Center National Institute for Health and Care Excellence, (accessed Jan 8, 2014). http://www.nice.org.uk/aboutnice/niceinternational/NICEInternationalChinaMoU.jsp.
80. About international outreach St Jude Children's Research Hospital, (accessed Jan 8, 2014). http://www.stjude.org/stjude/v/index.jsp?vgnextoid=2f166f9523e70110VgnVCM1000001e0215acRCRD&vgnextchannel=e41e6fa0a9118010VgnVCM1000000e2015acRCRD.
81. Improving health at home and abroad: how overseas volunteering from the NHS benefits the UK and the world All-Party Parliamentary Group on Global Health, (accessed Nov 21, 2013). http://www.rcpsych.ac.uk/pdf/Improving%20Health%20at%20Home%20and%20Abroad%20-%20Final%20Report.pdf.
82. Oxman AD, Lavis JN, Lewin S, Fretheim A SUPPORT Tools for evidence-informed health Policymaking (STP) 1: what is evidence-informed policymaking?. Health Res Policy Syst 2009, 7(suppl 1):S1.
83. Chalkidou K, Levine R, Dillon A Helping poorer countries make locally informed health decisions. BMJ 2010, 341:c3651.
84. Universal health coverage: a commitment to close the gap Rockefeller Foundation, Save the ChildrenSave the Children, UNICEFUNICEF, World Health OrganizationWorld Health Organization, (accessed Nov 21, 2013). http://www.savethechildren.org.uk/sites/default/files/images/Universal_health_coverage.pdf.
85. Johansson KA, Jerene D, Norheim OF National HIV treatment guidelines in Tanzania and Ethiopia: are they legitimate rationing tools?. J Med Ethics 2008, 34:478-483.
86. Marquez PV, Farrington JL No more disease silos for sub-Saharan Africa. BMJ 2012, 345:e5812.